Related Experiment Videos
Serum high-density lipoproteins cholesterol, heparin and peripheral vascular disease
Insights
Serum high-density lipoprotein cholesterol (HDL-C) was significantly lower in peripheral vascular disease (PVD) patients. Heparin treatment may influence HDL-C levels in PVD patients, warranting further investigation.
Area of Science:
- Cardiovascular Medicine
- Clinical Chemistry
Background:
- Peripheral vascular disease (PVD) is a significant health concern.
- High-density lipoprotein cholesterol (HDL-C) is a key lipid marker.
Purpose of the Study:
- To investigate HDL-C levels in patients with PVD compared to healthy controls.
- To explore the relationship between HDL-C, PVD, and other vascular risk factors.
- To assess the impact of heparin therapy on HDL-C levels in PVD patients.
Main Methods:
- Serum HDL-C levels were measured in 85 PVD patients and 72 healthy controls.
- Data were analyzed considering vascular risk factors like diabetes, smoking, and hypertension.
- A subgroup of 23 PVD patients receiving heparin was compared to those not on heparin therapy.
Main Results:
- Patients with PVD exhibited significantly decreased HDL-C levels compared to controls.
- No significant differences in HDL-C levels were observed concerning diabetes mellitus, smoking, or hypertension.
- PVD patients undergoing heparin treatment showed higher HDL-C levels than those not on heparin therapy.
Conclusions:
- Reduced HDL-C is associated with peripheral vascular disease.
- Heparin therapy may positively influence HDL-C levels in PVD patients.
- Further research is needed to understand the clinical implications of these findings.
Abstract:
Serum high-density lipoprotein cholesterol (HDL-C) has been determined in 85 patients with peripheral vascular disease (PVD) and in 72 healthy control subjects. HDL-C levels were significantly decreased in patients with PVD. Considering other vascular risk factors as diabetes mellitus, smoking and hypertension, there were no differences in HDL-C levels. Twenty-three patients received heparin as treatment, this subgroup showed a HDL-C levels higher than patients who were not under heparin therapy. The possible clinical implications of these facts are discussed.